However, due to drug resistance, trametinib has only been approved by the FDA, in combination with dabrafenib, for the treatment of BRAF-mutated metastatic melanoma and advanced non-small cell lung cancer. The gene discussed is BRAF; the disease is non-small cell lung carcinoma.